Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

The Global Pediatric Vaccines Market to 2024: Increase in the Government & Non-government Funding in R&D - ResearchAndMarkets.com

May 23, 2019

DUBLIN--(BUSINESS WIRE)--May 23, 2019--

The “Pediatric Vaccines Market - Growth, Trends, and Forecast (2019 - 2024)” report has been added to ResearchAndMarkets.com’s offering.

The global pediatric vaccine market is expected to register 11.7% CAGR during the forecast period 2019-2024.

The growth of the pediatric vaccines market is attributed due to the rising burden of chronic disease with the importance and awareness of immunization, technological advancements in vaccines, an increase in the government and non-government funding in R&D.

As immunization plays a significant role in modern medicine, there are several international programs for children, which may vary based on the disease. However, these programs are primarily driving the demand for the pediatric vaccines market.

There are several chronic diseases among children, which make them further susceptible to severe manifestations and complications with chronic diseases, For example, diseases, such as allergic, cardiorespiratory, hematologic, metabolic, and renal disorders, among others, lead to an increased risk of developing influenza, varicella, and pneumococcal infection. The parental understanding regarding these complications and immunization benefits is also required to raise awareness regarding pediatric vaccines.

The television, by far, is the most common source of information, followed by health professionals, newspapers, and magazines. The uptake of pediatric vaccination has improved through community-based vaccination program, which communicates the benefits and effectiveness of vaccines, hence promoting the growth of the pediatric vaccines market.

Furthermore, government initiatives, like Vaccines for Children Program, provides vaccines to children who lack health insurance or cannot afford the cost of vaccination, which is funded by the Centers for Medicare and Medicaid Services (CMS) to the Centers for Disease Control (CDC), and approved by the Office of Management and Budget.

The Conjugate Vaccine Segment, under Technology, is Expected to Grow at the Fastest Rate

The conjugate vaccine segment held a maximum share in 2018, and is likely to witness a rapid growth during the forecast period, due to the increasing prevalence of pneumococcal and meningococcal infections, and rise in the awareness regarding the prevention of infection, by government initiatives.

The North American Region Holds the Largest Market Share

North America is expected to be the primary region for the pediatric vaccines market, over the forecast period. The scheduled children immunization programs under the Centers for Disease Control and Prevention (CDC), high funding, wide commercial availability of vaccines, and the awareness in society regarding vaccines contribute to the sustained growth in the United States.

In Canada, the vaccination schedule for infants and children are regularly updated by the Government of Canada, in collaboration with the Canadian Nursing Coalition for Immunization (CNCI) and the Canadian Immunization Committee (CIC). The well-structured healthcare services boost the growth of the pediatric vaccines market in North America.

Competitive Landscape

The pediatric vaccines market consists of several major players, including GlaxoSmithKline PLC, Merck & Co. Inc., Novartis AG, etc. The companies are implementing certain strategic initiatives, such as mergers, new product launches, acquisitions, and partnerships, which help them in strengthening their market position.

Key Topics Covered


1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study




4.1 Market Overview

4.2 Market Drivers

4.2.1 Rising Burden of Chronic Diseases with the Importance & Awareness of Immunization

4.2.2 Technological Advancements in Vaccines

4.2.3 Increase in the Government & Non-government Funding in R&D

4.3 Market Restraints

4.3.1 Cost of Immunization

4.3.2 Low Medical Coverage and Healthcare Services in Low- and Middle-income Countries

4.4 Porter’s Five Forces Analysis


5.1 By Vaccine Type

5.1.1 Monovalent

5.1.2 Multivalent

5.2 By Technology

5.2.1 Live Attenuated

5.2.2 Inactivated

5.2.3 Toxoid

5.2.4 Conjugate

5.2.5 Other Technologies

5.3 By Application

5.3.1 Infectious Disease

5.3.2 Cancer

5.3.3 Allergy

5.3.4 Other Applications

5.4 Geography

5.4.1 North America US Canada Mexico

5.4.2 Europe Germany UK France Italy Spain Rest of Europe

5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific

5.4.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa

5.4.5 South America Brazil Argentina Rest of South America


6.1 Company Profiles

6.1.1 GlaxoSmithKline PLC

6.1.2 Indian Immunologicals Limited

6.1.3 AstraZeneca

6.1.4 Merck & Co. Inc.

6.1.5 Mitsubishi Tanabe Pharma Corporation

6.1.6 Novartis AG

6.1.7 Pfizer Inc.

6.1.8 Sanofi S.A.

6.1.9 Seqirus (CSL Limited)


For more information about this report visit https://www.researchandmarkets.com/r/1q2ipv

View source version on businesswire.com:https://www.businesswire.com/news/home/20190523005659/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Vaccines,Pediatrics



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/23/2019 01:08 PM/DISC: 05/23/2019 01:08 PM


All contents © copyright 2019 The Associated Press.All rights reserved.